H.C. Wainwright raised the firm’s price target on Kyverna Therapeutics (KYTX) to $20 from $10 and keeps a Buy rating on the shares. The firm upped its probability of approval for KYV-101 in myasthenia gravis to 35% from 25%, saying it has growing conviction in KYV-101’s “remarkable durability and immediacy of responses.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics price target raised to $27 from $24 at Wells Fargo
- Kyverna Therapeutics Announces Board Member Resignation
- Kyverna Therapeutics: Promising Potential in MS and MG with Strong Financials and Conservative Valuation
- Kyverna Therapeutics’ KYV-101: Promising Efficacy and Safety in Multiple Sclerosis and Beyond
- Kyverna Therapeutics announces updated data from Phase 1 IITs of KYV-101